Rua Bioscience CCO Steps Down

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com




FOR PUBLIC RELEASE
NZX Limited
Wellington

Tuesday, September 20, 2022


Rua Bioscience CCO Steps Down

Rua Bioscience (NZX: RUA) announces that Andi Grant is to step down from the role of Chief
Commercial Officer. The role will be filled by current Chief Operating Officer, Paul Naske.

Andi joined Rua in June 2021 and has substantially progressed Rua’s global and New Zealand
business goals.

Rua Managing Director, Anna Stove, says “Andi has significantly advanced our entry into
Germany, where we will launch by year’s end. Andi played a key role in the acquisition of
Zalm and has progressed our cultivation partnership with Cann Group which resulted from
that transaction. Andi also penned the recently announced five-year supply agreement with
Motagon, securing Rua’s entry into further high-value European markets”.

Ms Stove says Dr Grant has also made a difference in the lives of medicinal cannabis
patients throughout Aotearoa.

“Andi launched Rua’s first product here in New Zealand and established the domestic
industry’s first medicinal cannabis compassionate access programme, of which Rua is
incredibly proud,” she says.

“Andi is dynamic, tenacious and passionate and we’re grateful for her inspired mahi.”

Speaking about her departure, Dr Grant says “It has been a privilege to be a part of RUA’s
journey. I am proud of our achievements as a team, and I will always hold the people I have
had the opportunity of working alongside in the highest regard. With Paul ready and able to
take up the mantle, I am confident RUA will continue this path of commercial success and
fulfilment of its social mission to benefit its founding community”.

Paul Naske has been overseeing Rua’s topline business operations since the beginning of
2019 and has been critical in the design and efficient execution of Rua’s global strategy.

“Paul has been with Rua since the very early days and helped build our organisation. He
oversaw the construction of Rua’s two world-class medicinal cannabis facilities in
Mangaoporo and Gisborne. He supported the team through the GMP process and was

ANNOUNCEMENT

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com




instrumental in navigating the regulatory environment within which Rua launched its first
product for New Zealand patients,” says Ms Stove.

“As Rua has transitioned to commercialisation, Paul and Andi have worked closely to drive
the business forward. Paul’s knowledge of the commercial environment has ensured Rua’s
alignment with the business needs of our global clients. His expertise complements that of
Andi’s, so we expect a seamless transition over the next couple of months.”

ENDS


For more information, please contact:
Kerry Donovan
Communications Manager Rua Bioscience
Email: kerry.donovan@ruabio.com
Phone: 021 128 7689